相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian approach
Susanne Schmitz et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study
Aatke van der Maas et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry
Jeffrey D. Greenberg et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Changes in Utilization and Costs for Patients with Rheumatoid Arthritis, 1997 to 2006
Howard G. Birnbaum et al.
PHARMACOECONOMICS (2012)
Differential Expression of NK Receptors CD94 and NKG2A by T Cells in Rheumatoid Arthritis Patients in Remission Compared to Active Disease
Ceara E. Walsh et al.
PLOS ONE (2011)
Cost of illness in rheumatoid arthritis in Germany in 1997-98 and 2002: cost drivers and cost savings
Timm Kirchhoff et al.
RHEUMATOLOGY (2011)
Cost Effectiveness Analysis of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis. A Systematic Review Literature
Maurizio Benucci et al.
INTERNATIONAL JOURNAL OF RHEUMATOLOGY (2011)
Patients with rheumatoid arthritis treated with tumour necrosis factor antagonists increase their participation in the workforce: potential for significant long-term indirect cost gains (data from a population-based registry)
J. Augustsson et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Impact of adalimumab on work participation in rheumatoid arthritis: comparison of an open-label extension study and a registry-based control group
M. T. Halpern et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy
K. Pavelka et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Differences in Annual Medication Costs and Rates of Dosage Increase Between Tumor Necrosis Factor-Antagonist Therapies for Rheumatoid Arthritis in a Managed Care Population
Daniel A. Ollendorf et al.
CLINICAL THERAPEUTICS (2009)
Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study
B. J. F. van den Bemt et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Biologic drugs for rheumatoid arthritis in the medicare program
Allan J. Wailoo et al.
ARTHRITIS AND RHEUMATISM (2008)
Economic consequences of established rheumatoid arthritis and its treatment
Arthur Kavanaugh
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2007)
Double-blinded infliximab dose escalation in patients with rheumatoid arthritis
Mahboob U. Rahman et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis
R. M. Nixon et al.
STATISTICS IN MEDICINE (2007)
Dose escalation of the anti-TNF-α agents in patients with rheumatoid arthritis.: A systematic review
R. Ariza-Ariza et al.
RHEUMATOLOGY (2007)
The LUNDEX, a new index of drug efficacy in clinical practice - Results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden
LE Kristensen et al.
ARTHRITIS AND RHEUMATISM (2006)
Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis
James R. Spalding et al.
PHARMACOECONOMICS (2006)
Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry
AL Weaver et al.
CURRENT MEDICAL RESEARCH AND OPINION (2006)
A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study
P Durez et al.
RHEUMATOLOGY (2005)
The cost-effectiveness of infliximab (Remicade®) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study
G Kobelt et al.
RHEUMATOLOGY (2003)
Dose titration using the Disease Activity Score (DAS28) in rheumatoid arthritis patients treated with anti-TNF-α
AA den Broeder et al.
RHEUMATOLOGY (2002)
分享论文
